Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD1 | P21728 | 1/20 | 0.33 |
| ▸ | ATR | Q13535 | 3/20 | 0.32 |
| ▸ | RXRA | P19793 | 1/20 | 0.31 |
| ▸ | RXRB | P28702 | 1/20 | 0.31 |
| ▸ | RXRG | P48443 | 1/20 | 0.31 |
| ▸ | DGAT2 | Q96PD7 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5802425 | 0.90 | RXRA (0.35) | DRD1ATRRXRARXRBRXRG | |
| SCHEMBL4605947 | 0.90 | CMKLR1 (0.34) | DRD1ATRRXRARXRBRXRG | |
| SCHEMBL5374181 | 0.90 | DRD1 (0.33) | DRD1ATRRXRARXRBRXRG | |
| SCHEMBL5373368 | 0.88 | DRD1 (0.34) | DRD1ATRRXRARXRBRXRG | |
| SCHEMBL5377590 | 0.86 | ALDH1A1 (0.34) | DRD1 | |
| SCHEMBL5373140 | 0.86 | CPT2 (0.35) | DRD1ATRRXRARXRBRXRG | |
| SCHEMBL5388680 | 0.86 | CYP1A2 (0.37) | — | |
| SCHEMBL5377905 | 0.85 | DRD1 (0.34) | DRD1ATRRXRARXRBRXRG | |
| SCHEMBL5389006 | 0.85 | DRD1 (0.30) | DRD1RXRARXRBRXRG | |
| SCHEMBL5374237 | 0.85 | CNR1 (0.32) | DRD1RXRARXRBRXRGDGAT2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7220771-B2 | Methods of using indazole derivatives as JNK inhibitors | SIGNAL PHARMACEUTICALS, LLC (US) | 2007-05-22 | — | — | US | disclosed |
| US-20040077877-A1 | Indazole derivatives as JNK inhibitors and compositions and methods related thereto | SIGNAL PHARMACEUTICALS, INC. | 2004-04-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040077877-A1 | Indazole derivatives as JNK inhibitors and compositions and methods related thereto | MAP3K7, MAP3K1, MAP3K8 | DRD1 4315/4885ATR 1021/4885RXRA 988/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.